David Berger - Tandem Diabetes General Counsel
| TNDM Stock | USD 31.86 1.64 4.90% |
Executive
Mr. David B. Berger is an Executive Vice President, General Counsel, Secretary of Tandem Diabetes Care, Inc. He has served as our General Counsel since August 2013, as our Corporationrationrate Secretary since January 2015, and as our Executive Vice President since January 2016. Prior to joining our Company, from January 2008 until August 2013, he served as Vice President and General Counsel of Senomyx, and was promoted to Senior Vice President in January 2012. He also served as Corporationrationrate Secretary of Senomyx from January 2008 until May 2014. From April 2003 until October 2007, Mr. Berger was responsible for all commercial aspects of legal affairs at Biosite, most recently serving as Vice President, Legal Affairs. Previously, Mr. Berger was an attorney at Cooley Godward LLP and Amylin Pharmaceuticals, Inc since 2016.
| Age | 48 |
| Tenure | 8 years |
| Address | 12400 High Bluff Drive, San Diego, CA, United States, 92130 |
| Phone | 858 366 6900 |
| Web | https://www.tandemdiabetes.com |
Tandem Diabetes Management Efficiency
The company has return on total asset (ROA) of (0.0963) % which means that it has lost $0.0963 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5908) %, meaning that it created substantial loss on money invested by shareholders. Tandem Diabetes' management efficiency ratios could be used to measure how well Tandem Diabetes manages its routine affairs as well as how well it operates its assets and liabilities. As of the 16th of April 2024, Return On Tangible Assets is likely to drop to -0.25. In addition to that, Return On Capital Employed is likely to grow to -0.29. At this time, Tandem Diabetes' Intangible Assets are very stable compared to the past year. As of the 16th of April 2024, Net Tangible Assets is likely to grow to about 531.2 M, while Intangibles To Total Assets are likely to drop 0.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| John Duggan | Select Medical Holdings | N/A | |
| Elissa Charbonneau | Encompass Health Corp | 64 | |
| Cheryl Levy | Encompass Health Corp | 58 | |
| Langham MBA | Enhabit | 47 | |
| Lynette CPA | Pennant Group | 47 | |
| Andrew Price | Encompass Health Corp | 57 | |
| Kim Sullivan | Encompass Health Corp | N/A | |
| Mary Lacey | Select Medical Holdings | N/A | |
| Kirk Cheney | Pennant Group | N/A | |
| Dylan Black | Enhabit | 54 | |
| Bridget Sherick | Select Medical Holdings | N/A | |
| RN BSN | Enhabit | 66 | |
| Shelly Eckenroth | Select Medical Holdings | N/A | |
| Brian Rusignuolo | Select Medical Holdings | 48 | |
| Oleg Mikulinsky | CryoCell International | 51 | |
| Anderson Sr | National HealthCare | 62 | |
| Mark Brewer | Enhabit | N/A | |
| MS DO | Encompass Health Corp | 64 | |
Management Performance
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.0963 |
Tandem Diabetes Care Leadership Team
Elected by the shareholders, the Tandem Diabetes' board of directors comprises two types of representatives: Tandem Diabetes inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tandem. The board's role is to monitor Tandem Diabetes' management team and ensure that shareholders' interests are well served. Tandem Diabetes' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tandem Diabetes' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Tom Fox, Chief Officer | ||
| Rebecca Robertson, Independent Director | ||
| David Esq, Transitional Advisor | ||
| Libba Sapitsky, Senior Care | ||
| Dick Allen, Chairman of the Board | ||
| Douglas Roeder, Independent Director | ||
| Leigh Vosseller, Senior Vice President - Finance | ||
| Rick Carpenter, Chief Officer | ||
| Elizabeth Gasser, Executive Officer | ||
| Brian Hansen, Chief Commercial Officer, Executive Vice President | ||
| Fred Cohen, Independent Director | ||
| Susan Morrison, Chief Admin. Officer | ||
| Lori Gildea, Vice President - Sales | ||
| Howard Greene, Independent Director | ||
| Ross Sylvia, VP Marketing | ||
| Christopher Twomey, Independent Director | ||
| Jordan MD, Chief Officer | ||
| Henry Anhalt, Independent Director | ||
| Edward Cahill, Independent Director | ||
| Lonnie Smith, Chairman of the Board | ||
| John Cajigas, CFO and Executive VP | ||
| David Berger, General Counsel | ||
| Jesse Treu, Independent Director | ||
| Richard Valencia, Independent Director | ||
| John Sheridan, COO and Executive VP | ||
| Kim Blickenstaff, CEO and President and Director | ||
| Robert Anacone, Chief Commercial Officer and Executive VP | ||
| Shannon Hansen, Privacy Legal |
Tandem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tandem Diabetes a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.59 | ||||
| Return On Asset | -0.0963 | ||||
| Profit Margin | (0.30) % | ||||
| Operating Margin | (0.18) % | ||||
| Current Valuation | 2.15 B | ||||
| Shares Outstanding | 64.56 M | ||||
| Shares Owned By Insiders | 0.60 % | ||||
| Shares Owned By Institutions | 99.40 % | ||||
| Number Of Shares Shorted | 9.31 M | ||||
| Price To Earning | 494.25 X |
Tandem Diabetes Investors Sentiment
The influence of Tandem Diabetes' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Tandem. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Tandem Diabetes' public news can be used to forecast risks associated with an investment in Tandem. The trend in average sentiment can be used to explain how an investor holding Tandem can time the market purely based on public headlines and social activities around Tandem Diabetes Care. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Tandem Diabetes' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Tandem Diabetes' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Tandem Diabetes' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Tandem Diabetes.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Tandem Diabetes in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Tandem Diabetes' short interest history, or implied volatility extrapolated from Tandem Diabetes options trading.
Currently Active Assets on Macroaxis
| LTC | Litecoin | |
| STETH | Staked Ether | |
| LINK | Chainlink | |
| XLM | Stellar | |
| CRO | Cronos |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tandem Diabetes Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Tandem Diabetes Care information on this page should be used as a complementary analysis to other Tandem Diabetes' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Complementary Tools for Tandem Stock analysis
When running Tandem Diabetes' price analysis, check to measure Tandem Diabetes' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tandem Diabetes is operating at the current time. Most of Tandem Diabetes' value examination focuses on studying past and present price action to predict the probability of Tandem Diabetes' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tandem Diabetes' price. Additionally, you may evaluate how the addition of Tandem Diabetes to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Stocks Directory Find actively traded stocks across global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets |
Is Tandem Diabetes' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tandem Diabetes. If investors know Tandem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tandem Diabetes listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.37) | Earnings Share (3.43) | Revenue Per Share 11.509 | Quarterly Revenue Growth (0.11) | Return On Assets (0.1) |
The market value of Tandem Diabetes Care is measured differently than its book value, which is the value of Tandem that is recorded on the company's balance sheet. Investors also form their own opinion of Tandem Diabetes' value that differs from its market value or its book value, called intrinsic value, which is Tandem Diabetes' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tandem Diabetes' market value can be influenced by many factors that don't directly affect Tandem Diabetes' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tandem Diabetes' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tandem Diabetes is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tandem Diabetes' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.